Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC
These findings reveal a complex interplay between SABR and immunotherapy, with potentially valuable implications for treatment strategies involving SABR and immunotherapy to induce systemic T cell responses for tumor eradication in patients with NSCLC.
Authors
- Bing Sun (ORCID: https://orcid.org/0000-0002-7040-0902)
- Jingyang Zhu
- Zongcheng Li (ORCID: https://orcid.org/0000-0002-5189-5268)
- Chao Liu (ORCID: https://orcid.org/0000-0001-5886-4264)
- Meilin Jiang (ORCID: https://orcid.org/0000-0003-4515-4567)
- Xiaohui Li (ORCID: https://orcid.org/0000-0001-9653-9227)
- Bing Liu (ORCID: https://orcid.org/0000-0002-6825-3536)
- Fuhao Wang (ORCID: https://orcid.org/0009-0008-3636-1437)
- Zhijie Bai (ORCID: https://orcid.org/0000-0003-4453-8278)
- Qingyu Huang (ORCID: https://orcid.org/0009-0009-9763-5283)
- Yanjuan Chen (ORCID: https://orcid.org/0000-0002-9371-0313)
- Rui Huang (ORCID: https://orcid.org/0000-0002-3048-2835)
- Dongsheng Sheng
- Wenxue Zou
- Huiru Sun
Institutions
- Jinan University (CN)
- Peking University (CN)
- Chinese PLA General Hospital (CN)
- Shandong Tumor Hospital (CN)
- Peking University First Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s00262-024-03935-8
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province